Currently out of the existing stock ratings of Esther Rajavelu, 48 are a BUY (77.42%), 7 are a SELL (11.29%), 7 are a HOLD (11.29%).

Esther Rajavelu

Work Performance Price Targets & Ratings Chart

Analyst Esther Rajavelu works with a stock forecast success ratio of 54.17% fulfilled within 190.94 days on average. Previously, Esther Rajavelu worked at UBS.

Esther Rajavelu’s has documented 139 price targets and ratings displayed on 17 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RGNX, Regenxbio at 17-Jan-2024.

Wall Street Analyst Esther Rajavelu

Analyst best performing recommendations are on VNDA (VANDA PHARMACEUTICALS).
The best stock recommendation documented was for VNDA (VANDA PHARMACEUTICALS) at 2/14/2019. The price target of $21 was fulfilled within 1 day with a profit of $0.88 (4.37%) receiving and performance score of 43.74.

Average potential price target upside

of $41.31 (36.02%) on GWPH (GW PHARMACEUTICALS PLC).
of $36.27 (27.75%) on JAZZ (JAZZ PHARMACEUTICALS PLC).
of $34.05 (20.32%) on ALNY (ALNYLAM PHARMACEUTICALS).

ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd GWPH GW Pharmaceuticals plc IONS Ionis Pharmaceuticals KOD Kodiak Sciences RGNX Regenxbio JAZZ Jazz Pharmaceuticals PLC LGND Ligand Pharmaceuticals orporated TEVA Teva Pharma Industries Ltd ADR AERI Aerie Pharmaceuticals . TXMD TherapeuticsMD VNDA Vanda Pharmaceuticals NVCR Novocure Ltd ORTX Orchard Therapeutics PLC OTIC Otonomy RCKT Rocket Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Keay Nakae (CHARDAN CAPITAL)